{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:32:13Z","timestamp":1786980733595,"version":"build-2736575974"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2015,4,3]],"date-time":"2015-04-03T00:00:00Z","timestamp":1428019200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Apoptosis"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1007\/s10495-015-1125-1","type":"journal-article","created":{"date-parts":[[2015,4,3]],"date-time":"2015-04-03T09:19:58Z","timestamp":1428052798000},"page":"975-985","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["The synergistic effect of BCR signaling inhibitors combined with an HDAC inhibitor on cell death in a mantle cell lymphoma cell line"],"prefix":"10.1007","volume":"20","author":[{"given":"Kazumi","family":"Hagiwara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Kunishima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroatsu","family":"Iida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiko","family":"Miyata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Naoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,4,3]]},"reference":[{"issue":"3","key":"1125_CR1","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/nrd3937","volume":"12","author":"RM Young","year":"2013","unstructured":"Young RM, Staudt LM (2013) Targeting pathological B cell receptor signalling in lymphoid malignancies. Nat Rev Drug Discov 12(3):229\u2013243. doi: 10.1038\/nrd3937","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"1125_CR2","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2010-04-189977","volume":"117","author":"P Perez-Galan","year":"2011","unstructured":"Perez-Galan P, Dreyling M, Wiestner A (2011) Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood 117(1):26\u201338. doi: 10.1182\/blood-2010-04-189977","journal-title":"Blood"},{"issue":"10","key":"1125_CR3","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nrc2230","volume":"7","author":"P Jares","year":"2007","unstructured":"Jares P, Colomer D, Campo E (2007) Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer 7(10):750\u2013762. doi: 10.1038\/nrc2230","journal-title":"Nat Rev Cancer"},{"issue":"7277","key":"1125_CR4","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nature08638","volume":"463","author":"RE Davis","year":"2010","unstructured":"Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, Kohlhammer H, Lamy L, Zhao H, Yang Y, Xu W, Shaffer AL, Wright G, Xiao W, Powell J, Jiang JK, Thomas CJ, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Connors JM, Johnson NA, Rimsza LM, Campo E, Jaffe ES, Wilson WH, Delabie J, Smeland EB, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Pierce SK, Staudt LM (2010) Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 463(7277):88\u201392. doi: 10.1038\/nature08638","journal-title":"Nature"},{"issue":"3","key":"1125_CR5","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1365-2141.2005.05883.x","volume":"132","author":"A Rinaldi","year":"2006","unstructured":"Rinaldi A, Kwee I, Taborelli M, Largo C, Uccella S, Martin V, Poretti G, Gaidano G, Calabrese G, Martinelli G, Baldini L, Pruneri G, Capella C, Zucca E, Cotter FE, Cigudosa JC, Catapano CV, Tibiletti MG, Bertoni F (2006) Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma. Br J Haematol 132(3):303\u2013316. doi: 10.1111\/j.1365-2141.2005.05883.x","journal-title":"Br J Haematol"},{"key":"1125_CR6","first-page":"47","volume":"7","author":"K Ververis","year":"2013","unstructured":"Ververis K, Hiong A, Karagiannis TC, Licciardi PV (2013) Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents. Biologics 7:47\u201360. doi: 10.2147\/BTT.S29965","journal-title":"Biologics"},{"key":"1125_CR7","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1756-8722-2-31","volume":"2","author":"D Siegel","year":"2009","unstructured":"Siegel D, Hussein M, Belani C, Robert F, Galanis E, Richon VM, Garcia-Vargas J, Sanz-Rodriguez C, Rizvi S (2009) Vorinostat in solid and hematologic malignancies. J Hematol Oncol 2:31. doi: 10.1186\/1756-8722-2-31","journal-title":"J Hematol Oncol"},{"issue":"7","key":"1125_CR8","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1182\/blood-2005-11-026344","volume":"110","author":"N Kawamata","year":"2007","unstructured":"Kawamata N, Chen J, Koeffler HP (2007) Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells. Blood 110(7):2667\u20132673. doi: 10.1182\/blood-2005-11-026344","journal-title":"Blood"},{"issue":"1","key":"1125_CR9","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.exphem.2004.09.008","volume":"33","author":"S Sakajiri","year":"2005","unstructured":"Sakajiri S, Kumagai T, Kawamata N, Saitoh T, Said JW, Koeffler HP (2005) Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines. Exp Hematol 33(1):53\u201361. doi: 10.1016\/j.exphem.2004.09.008","journal-title":"Exp Hematol"},{"issue":"1","key":"1125_CR10","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1600-0609.2005.00546.x","volume":"76","author":"U Heider","year":"2006","unstructured":"Heider U, Kaiser M, Sterz J, Zavrski I, Jakob C, Fleissner C, Eucker J, Possinger K, Sezer O (2006) Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma. Eur J Haematol 76(1):42\u201350. doi: 10.1111\/j.1600-0609.2005.00546.x","journal-title":"Eur J Haematol"},{"issue":"9","key":"1125_CR11","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1200\/JCO.2010.32.1398","volume":"29","author":"M Kirschbaum","year":"2011","unstructured":"Kirschbaum M, Frankel P, Popplewell L, Zain J, Delioukina M, Pullarkat V, Matsuoka D, Pulone B, Rotter AJ, Espinoza-Delgado I, Nademanee A, Forman SJ, Gandara D, Newman E (2011) Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin\u2019s lymphoma and mantle cell lymphoma. J Clin Oncol 29(9):1198\u20131203. doi: 10.1200\/JCO.2010.32.1398","journal-title":"J Clin Oncol"},{"issue":"2","key":"1125_CR12","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1600-0609.2007.00995.x","volume":"80","author":"U Heider","year":"2008","unstructured":"Heider U, von Metzler I, Kaiser M, Rosche M, Sterz J, Rotzer S, Rademacher J, Jakob C, Fleissner C, Kuckelkorn U, Kloetzel PM, Sezer O (2008) Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma. Eur J Haematol 80(2):133\u2013142. doi: 10.1111\/j.1600-0609.2007.00995.x","journal-title":"Eur J Haematol"},{"issue":"4","key":"1125_CR13","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.exphem.2007.12.008","volume":"36","author":"VY Yazbeck","year":"2008","unstructured":"Yazbeck VY, Buglio D, Georgakis GV, Li Y, Iwado E, Romaguera JE, Kondo S, Younes A (2008) Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma. Exp Hematol 36(4):443\u2013450. doi: 10.1016\/j.exphem.2007.12.008","journal-title":"Exp Hematol"},{"issue":"2","key":"1125_CR14","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/sj.leu.2404471","volume":"21","author":"T Haritunians","year":"2007","unstructured":"Haritunians T, Mori A, O\u2019Kelly J, Luong QT, Giles FJ, Koeffler HP (2007) Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma. Leukemia 21(2):333\u2013339. doi: 10.1038\/sj.leu.2404471","journal-title":"Leukemia"},{"issue":"13","key":"1125_CR15","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.4161\/cbt.8.13.8726","volume":"8","author":"R Rao","year":"2009","unstructured":"Rao R, Lee P, Fiskus W, Yang Y, Joshi R, Wang Y, Buckley K, Balusu R, Chen J, Koul S, Joshi A, Upadhyay S, Tao J, Sotomayor E, Bhalla KN (2009) Co-treatment with heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin (DMAG) and vorinostat: a highly active combination against human mantle cell lymphoma (MCL) cells. Cancer Biol Ther 8(13):1273\u20131280","journal-title":"Cancer Biol Ther"},{"issue":"1","key":"1125_CR16","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa M, Goto S (2000) KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res 28(1):27\u201330","journal-title":"Nucleic Acids Res"},{"key":"1125_CR17","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","volume":"22","author":"TC Chou","year":"1984","unstructured":"Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27\u201355","journal-title":"Adv Enzyme Regul"},{"issue":"10","key":"1125_CR18","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.leukres.2013.07.028","volume":"37","author":"M Cinar","year":"2013","unstructured":"Cinar M, Hamedani F, Mo Z, Cinar B, Amin HM, Alkan S (2013) Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis. Leuk Res 37(10):1271\u20131277. doi: 10.1016\/j.leukres.2013.07.028","journal-title":"Leuk Res"},{"issue":"33","key":"1125_CR19","doi-asserted-by":"crossref","first-page":"14639","DOI":"10.1073\/pnas.1008522107","volume":"107","author":"JH Lee","year":"2010","unstructured":"Lee JH, Choy ML, Ngo L, Foster SS, Marks PA (2010) Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair. Proc Natl Acad Sci USA 107(33):14639\u201314644. doi: 10.1073\/pnas.1008522107","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"1125_CR20","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1172\/JCI61272","volume":"122","author":"P Jares","year":"2012","unstructured":"Jares P, Colomer D, Campo E (2012) Molecular pathogenesis of mantle cell lymphoma. J Clin Invest 122(10):3416\u20133423. doi: 10.1172\/JCI61272","journal-title":"J Clin Invest"},{"issue":"6","key":"1125_CR21","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.leukres.2012.01.027","volume":"36","author":"W Shi","year":"2012","unstructured":"Shi W, Han X, Yao J, Yang J, Shi Y (2012) Combined effect of histone deacetylase inhibitor suberoylanilide hydroxamic acid and anti-CD20 monoclonal antibody rituximab on mantle cell lymphoma cells apoptosis. Leuk Res 36(6):749\u2013755. doi: 10.1016\/j.leukres.2012.01.027","journal-title":"Leuk Res"},{"issue":"3","key":"1125_CR22","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1124\/jpet.106.109058","volume":"319","author":"S Braselmann","year":"2006","unstructured":"Braselmann S, Taylor V, Zhao H, Wang S, Sylvain C, Baluom M, Qu K, Herlaar E, Lau A, Young C, Wong BR, Lovell S, Sun T, Park G, Argade A, Jurcevic S, Pine P, Singh R, Grossbard EB, Payan DG, Masuda ES (2006) R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. J Pharmacol Exp Ther 319(3):998\u20131008. doi: 10.1124\/jpet.106.109058","journal-title":"J Pharmacol Exp Ther"},{"issue":"13","key":"1125_CR23","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1182\/blood-2009-08-236471","volume":"115","author":"JW Friedberg","year":"2010","unstructured":"Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A, Schaefer-Cutillo J, De Vos S, Sinha R, Leonard JP, Cripe LD, Gregory SA, Sterba MP, Lowe AM, Levy R, Shipp MA (2010) Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 115(13):2578\u20132585. doi: 10.1182\/blood-2009-08-236471","journal-title":"Blood"},{"issue":"6","key":"1125_CR24","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","volume":"369","author":"ML Wang","year":"2013","unstructured":"Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Li L, Zhang L, Newberry K, Ou Z, Cheng N, Fang B, McGreivy J, Clow F, Buggy JJ, Chang BY, Beaupre DM, Kunkel LA, Blum KA (2013) Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 369(6):507\u2013516. doi: 10.1056\/NEJMoa1306220","journal-title":"N Engl J Med"},{"issue":"11","key":"1125_CR25","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/S0960-894X(03)00286-5","volume":"13","author":"MM Faul","year":"2003","unstructured":"Faul MM, Gillig JR, Jirousek MR, Ballas LM, Schotten T, Kahl A, Mohr M (2003) Acyclic N-(azacycloalkyl)bisindolylmaleimides: isozyme selective inhibitors of PKCbeta. Bioorg Med Chem Lett 13(11):1857\u20131859","journal-title":"Bioorg Med Chem Lett"},{"issue":"16","key":"1125_CR26","doi-asserted-by":"crossref","first-page":"7462","DOI":"10.1158\/0008-5472.CAN-05-0071","volume":"65","author":"JR Graff","year":"2005","unstructured":"Graff JR, McNulty AM, Hanna KR, Konicek BW, Lynch RL, Bailey SN, Banks C, Capen A, Goode R, Lewis JE, Sams L, Huss KL, Campbell RM, Iversen PW, Neubauer BL, Brown TJ, Musib L, Geeganage S, Thornton D (2005) The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res 65(16):7462\u20137469. doi: 10.1158\/0008-5472.can-05-0071","journal-title":"Cancer Res"},{"issue":"11","key":"1125_CR27","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1002\/gcc.21985","volume":"51","author":"K Hagiwara","year":"2012","unstructured":"Hagiwara K, Ito H, Murate T, Miyata Y, Ohashi H, Nagai H (2012) PROX1 overexpression inhibits protein kinase C beta II transcription through promoter DNA methylation. Genes Chromosomes Cancer 51(11):1024\u20131036. doi: 10.1002\/gcc.21985","journal-title":"Genes Chromosomes Cancer"},{"issue":"5","key":"1125_CR28","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2559.2007.02666.x","volume":"50","author":"AV Decouvelaere","year":"2007","unstructured":"Decouvelaere AV, Morschhauser F, Buob D, Copin MC, Dumontet C (2007) Heterogeneity of protein kinase C beta(2) expression in lymphoid malignancies. Histopathology 50(5):561\u2013566. doi: 10.1111\/j.1365-2559.2007.02666.x","journal-title":"Histopathology"},{"issue":"5","key":"1125_CR29","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1182\/blood-2006-04-015586","volume":"108","author":"M Rudelius","year":"2006","unstructured":"Rudelius M, Pittaluga S, Nishizuka S, Pham TH, Fend F, Jaffe ES, Quintanilla-Martinez L, Raffeld M (2006) Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma. Blood 108(5):1668\u20131676. doi: 10.1182\/blood-2006-04-015586","journal-title":"Blood"},{"issue":"2","key":"1125_CR30","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/annonc\/mdm463","volume":"19","author":"F Morschhauser","year":"2008","unstructured":"Morschhauser F, Seymour JF, Kluin-Nelemans HC, Grigg A, Wolf M, Pfreundschuh M, Tilly H, Raemaekers J, van \u2018t Veer MB, Milpied N, Cartron G, Pezzutto A, Spencer A, Reyes F, Dreyling M (2008) A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma. Ann Oncol 19(2):247\u2013253. doi: 10.1093\/annonc\/mdm463","journal-title":"Ann Oncol"},{"issue":"9","key":"1125_CR31","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1007\/s10495-011-0617-x","volume":"16","author":"J Bodo","year":"2011","unstructured":"Bodo J, Sedlak J, Maciejewski JP, Almasan A, Hsi ED (2011) HDAC inhibitors potentiate the apoptotic effect of enzastaurin in lymphoma cells. Apoptosis 16(9):914\u2013923. doi: 10.1007\/s10495-011-0617-x","journal-title":"Apoptosis"},{"issue":"1","key":"1125_CR32","doi-asserted-by":"crossref","first-page":"88","DOI":"10.4049\/jimmunol.171.1.88","volume":"171","author":"LV Pham","year":"2003","unstructured":"Pham LV, Tamayo AT, Yoshimura LC, Lo P, Ford RJ (2003) Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol 171(1):88\u201395","journal-title":"J Immunol"},{"issue":"2","key":"1125_CR33","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s13148-010-0018-y","volume":"2","author":"ZY Guo","year":"2011","unstructured":"Guo ZY, Hao XH, Tan FF, Pei X, Shang LM, Jiang XL, Yang F (2011) The elements of human cyclin D1 promoter and regulation involved. Clin Epigenetics 2(2):63\u201376. doi: 10.1007\/s13148-010-0018-y","journal-title":"Clin Epigenetics"},{"issue":"2","key":"1125_CR34","first-page":"595","volume":"16","author":"L Sevilla","year":"2001","unstructured":"Sevilla L, Zaldumbide A, Pognonec P, Boulukos KE (2001) Transcriptional regulation of the bcl-x gene encoding the anti-apoptotic Bcl-xL protein by Ets, Rel\/NFkappaB, STAT and AP1 transcription factor families. Histol Histopathol 16(2):595\u2013601","journal-title":"Histol Histopathol"}],"container-title":["Apoptosis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-015-1125-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10495-015-1125-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-015-1125-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T14:41:38Z","timestamp":1559140898000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10495-015-1125-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,3]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["1125"],"URL":"https:\/\/doi.org\/10.1007\/s10495-015-1125-1","relation":{},"ISSN":["1360-8185","1573-675X"],"issn-type":[{"value":"1360-8185","type":"print"},{"value":"1573-675X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,3]]}}}